Circuit lifespan during continuous renal replacement therapy for combined liver and kidney failure

Journal of Critical Care

Volumn 27, Issue 6, 2012, Pages 744.e7-744.e15

  Chua, Horng Ruey ^a,d   Baldwin, Ian ^a,b   Bailey, Michael ^c   Subramaniam, Ashwin ^a   Bellomo, Rinaldo ^a,c  

^a AUSTIN HOSPITAL   (Australia)

^b RMIT UNIVERSITY   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Acute kidney injury; Acute liver failure; Bleeding risk; Circuit life; Cirrhosis; Continuous renal replacement therapy; Decompensated chronic liver disease; No anticoagulation; Thrombocytopenia

Indexed keywords

BILIRUBIN; HEPARIN; VASOACTIVE AGENT;

ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ADULT; ANTICOAGULANT THERAPY; ARTERY BLEEDING; ARTICLE; ARTIFICIAL VENTILATION; BILIRUBIN BLOOD LEVEL; BLEEDING; CIRCUIT LIFESPAN; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DECOMPENSATED LIVER CIRRHOSIS; DRUG USE; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPARINIZATION; HUMAN; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; INTRAABDOMINAL BLEEDING; MAJOR CLINICAL STUDY; MALE; MUCOSAL BLEEDING; PARTIAL THROMBOPLASTIN TIME; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 84870713870     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2012.08.016     Document Type: Article

References (41)

1. Karvellas C.J., Pink F., McPhail M., et al. Bacteremia, acute physiology and chronic health evaluation II and modified end stage liver disease are independent predictors of mortality in critically ill nontransplanted patients with acute on chronic liver failure. Crit Care Med 2010, 38:121-126.
2. Nair S., Verma S., Thuluvath P.J. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002, 35:1179-1185.
3. Wu C.C., Yeung L.K., Tsai W.S., et al. Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. Clin Nephrol 2006, 65:28-33.
4. Wong L.P., Blackley M.P., Andreoni K.A., et al. Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int 2005, 68:362-370.
5. Shellman R.G., Fulkerson W.J., DeLong E., et al. Prognosis of patients with cirrhosis and chronic liver disease admitted to the medical intensive care unit. Crit Care Med 1988, 16:671-678.
6. Davenport A., Will E.J., Davison A.M., et al. Changes in intracranial pressure during haemofiltration in oliguric patients with grade IV hepatic encephalopathy. Nephron 1989, 53:142-146.
7. Davenport A., Will E.J., Davidson A.M. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 1993, 21:328-338.
8. Uchino S., Fealy N., Baldwin I., et al. Continuous is not continuous: the incidence and impact of circuit "down-time" on uraemic control during continuous veno-venous haemofiltration. Intensive Care Med 2003, 29:575-578.
9. Cutts M.W., Thomas A.N., Kishen R. Transfusion requirements during continuous veno-venous haemofiltration: the importance of filter life. Intensive Care Med 2000, 26:1694-1697.
10. Meier-Kriesche H.U., Gitomer J., Finkel K., et al. Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med 2001, 29:748-752.
11. Bouchard J., Madore F. Role of citrate and other methods of anticoagulation in patients with severe liver failure requiring continuous renal replacement therapy. Nephrol Dial Transplant Plus 2009, 2:11-19.
12. Bellomo R., Ronco C., Kellum J.A., et al. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8:R204-R212.
13. Polson J., Lee W.M. AASLD position paper: the management of acute liver failure. Hepatology 2005, 41:1179-1197.
14. Bernal W., Auzinger G., Dhawan A., et al. Acute liver failure. Lancet 2010, 376:190-201.
15. Runyon B.A. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009, 49:2087-2107.
16. Yantorno S.E., Kremers W.K., Ruf A.E., et al. MELD is superior to King's college and Clichy's criteria to assess prognosis in fulminant hepatic failure. Liver Transpl 2007, 13:822-828.
17. Freeman R.B., Wiesner R.H., Harper A., et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002, 8:851-858.
18. Agarwal B., Shaw S., Hari M.S., et al. Continuous renal replacement therapy (CRRT) in patients with liver disease: is circuit life different?. J Hepatol 2009, 51:504-509.
19. Goulis J., Chau T.N., Jordan S., et al. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999, 44:754-758.
20. Bashour F.N., Teran J.C., Mullen K.D. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000, 95:2936-2939.
21. Lisman T., Bongers T.N., Adelmeijer J., et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006, 44:53-61.
22. Uemura M., Fujimura Y., Matsumoto M., et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008, 99:1019-1029.
23. Tan H.K., Baldwin I., Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med 2000, 26:1652-1657.
24. Holt A.W., Bierer P., Glover P., et al. Conventional coagulation and thromboelastograph parameters and longevity of continuous renal replacement circuits. Intensive Care Med 2002, 28:1649-1655.
25. Uchino S., Fealy N., Baldwin I., et al. Continuous venovenous hemofiltration without anticoagulation. ASAIO J 2004, 50:76-80.
26. Morabito S., Guzzo I., Solazzo A., et al. Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding. J Nephrol 2003, 16:566-571.
27. Tripodi A., Primignani M., Chantarangkul V., et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009, 137:2105-2111.
28. Tripodi A., Primignani M., Lemma L., et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology 2010, 52:249-255.
29. Lisman T., Caldwell S.H., Burroughs A.K., et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol 2010, 53:362-371.
30. Tripodi A., Mannucci P.M. The coagulopathy of chronic liver disease. N Engl J Med 2011, 365:147-156.
31. Kerr R., Newsome P., Germain L., et al. Effects of acute liver injury on blood coagulation. J Thromb Haemost : JTH 2003, 1:754-759.
32. Pernambuco J.R., Langley P.G., Hughes R.D., et al. Activation of the fibrinolytic system in patients with fulminant liver failure. Hepatology 1993, 18:1350-1356.
33. Thachil J. Relevance of clotting tests in liver disease. Postgrad Med J 2008, 84:177-181.
34. van de Wetering J., Westendorp R.G., van der Hoeven J.G., et al. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol : JASN 1996, 7:145-150.
35. Sakr Y. Heparin-induced thrombocytopenia in the ICU: an overview. Crit Care 2011, 15:211.
36. Levi M., Opal S.M. Coagulation abnormalities in critically ill patients. Crit Care 2006, 10:222.
37. Davenport A., Will E.J., Davison A.M. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron 1994, 66:431-437.
38. Davenport A., Will E.J., Davison A.M. Adverse effects on cerebral perfusion of prostacyclin administered directly into patients with fulminant hepatic failure and acute renal failure. Nephron 1991, 59:449-454.
39. Balogun R.A., Turgut F., Caldwell S., et al. Regional citrate anticoagulation in critically ill patients with liver and kidney failure. J Nephrol 2011.
40. Faybik P., Hetz H., Mitterer G., et al. Regional citrate anticoagulation in patients with liver failure supported by a molecular adsorbent recirculating system. Crit Care Med 2011, 39:273-279.
41. Bachli E.B., Bosiger J., Bechir M., et al. Thromboelastography to monitor clotting/bleeding complications in patients treated with the molecular adsorbent recirculating system. Crit Care Res Pract 2011, 2011:313854.